NL
DE
16 July 2019
Reinout van Crevel and Lindsey te Brake have received European funding (4,8 million euros) to lead an international consortium to screen thousands of people with diabetes in Uganda and Tanzania for TB, and investigate the effect and costs of 3 months preventive treatment for TB.
Tuberculosis affects> 10 million people annually and more than 1 million people die from the disease. Moreover, an estimated one quarter of the world's population is infected with Mycobacterium tuberculosis and they have a lifelong risk of getting active tuberculosis.
It is impossible to reduce tuberculosis without paying attention to the large group with "latent tuberculosis infection". High-risk groups such as small children and HIV-infected people are therefore already being treated preventively. People with diabetes could be a logical next group, but this has not yet been investigated.
In recent years, Reinout van Crevel has led a major international initiative "TANDEM" (which stands for "tuberculosis and diabetes mellitus") with a combination of clinical studies in Africa, Peru, Romania and Indonesia, and laboratory research in Radboudumc and other laboratories. TANDEM has provided many new insights, for example with regard to the greatly increased risk of tuberculosis with the combination of diabetes and latent tuberculosis. And now the work of TANDEM can be continued with this large - and first - clinical trial to investigate preventive treatment for TB in people with diabetes, including looking at screening, costs, quality of care and epidemiological effects of diabetes on TB in Africa.
Reinout van Crevel and Lindsey te Brake are members of theme Infectious diseases and global health.
Reinout van Crevel and Lindsey te Brake have received European funding (4,8 million euros) to lead an international consortium to screen thousands of people with diabetes in Uganda and Tanzania for TB, and investigate the effect and costs of 3 months preventive treatment for TB.
Tuberculosis affects> 10 million people annually and more than 1 million people die from the disease. Moreover, an estimated one quarter of the world's population is infected with Mycobacterium tuberculosis and they have a lifelong risk of getting active tuberculosis.
It is impossible to reduce tuberculosis without paying attention to the large group with "latent tuberculosis infection". High-risk groups such as small children and HIV-infected people are therefore already being treated preventively. People with diabetes could be a logical next group, but this has not yet been investigated.
In recent years, Reinout van Crevel has led a major international initiative "TANDEM" (which stands for "tuberculosis and diabetes mellitus") with a combination of clinical studies in Africa, Peru, Romania and Indonesia, and laboratory research in Radboudumc and other laboratories. TANDEM has provided many new insights, for example with regard to the greatly increased risk of tuberculosis with the combination of diabetes and latent tuberculosis. And now the work of TANDEM can be continued with this large - and first - clinical trial to investigate preventive treatment for TB in people with diabetes, including looking at screening, costs, quality of care and epidemiological effects of diabetes on TB in Africa.
Reinout van Crevel and Lindsey te Brake are members of theme Infectious diseases and global health.
Related news items
Antibodies are sustained in nasal fluid after mild corona infection
27 September 2021 Testing through nasal fluids is easier than through blood read more
Less inflammation with a traditional Tanzanian diet than with a Western diet
18 February 2021 Study shows differences between western and traditional diet. read more
Trained immunity: a tool for reducing susceptibility to and the severity of SARS-CoV-2 infection
17 February 2021 In a review in Cell Mihai Netea, Frank van de Veerdonk, Reinout van Crevel and Jorge Dominguez Andres propose that induction of trained immunity by whole-microorganism vaccines may represent an important tool for reducing susceptibility to and severity of SARS-CoV-2. read more
ZonMw grants to study optimal use of COVID-19 vaccines in patients with impaired immune systems
3 February 2021 How do people with reduced immunity, especially kidney patients, react to a COVID-19 vaccination? And how can patients with peripheral arterial disease be helped by DNA testing? Our researchers received grants from ZonMw to make these studies possible. read more
